GW3965 HYDROCHLORIDE NO FURTHER A MYSTERY

All enrolled people who obtained at the very least just one dose of zosuquidar or placebo through induction have been monitored with the event of adverse events (439 people, 219 on zosuquidar and 210 on placebo). The most common adverse activities ended up associated with the period of prolonged and considerable myelosuppression as is anticipated w